[go: up one dir, main page]

UA5560A1 - СПОСІБ РОЗДІЛЕННЯ СУМІШИ d-І l-ЕНАНТІОМЕРІВ 4-[1- - Google Patents

СПОСІБ РОЗДІЛЕННЯ СУМІШИ d-І l-ЕНАНТІОМЕРІВ 4-[1-

Info

Publication number
UA5560A1
UA5560A1 UA4356076A UA4356076A UA5560A1 UA 5560 A1 UA5560 A1 UA 5560A1 UA 4356076 A UA4356076 A UA 4356076A UA 4356076 A UA4356076 A UA 4356076A UA 5560 A1 UA5560 A1 UA 5560A1
Authority
UA
Ukraine
Prior art keywords
mixture
separation
enanthiomers
dimethylphenyl
imidazole
Prior art date
Application number
UA4356076A
Other languages
English (en)
Russian (ru)
Inventor
Йоханнес Карьялайнен Арто
Ейнарі Віртанен Раімо
Юхані Саволайнен Ейно
Original Assignee
Оріон Іхтюмя Ой
Орион Ихтюмя Ой
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10620775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA5560(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Оріон Іхтюмя Ой, Орион Ихтюмя Ой filed Critical Оріон Іхтюмя Ой
Publication of UA5560A1 publication Critical patent/UA5560A1/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Optical Record Carriers And Manufacture Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Заявлено спосіб розділення суміші D- і L-енантіомерів 4-[1-(2,3-диметилфеніл)етил]-1Н-імідазолу. Відповідно до способу рацемічний 4-[1-(2,3-диметилфеніл)-1-етил]імідазол обробляють оптично активною кислотою з подальшим розділенням суміші діастереоізомерних солей шляхом фракційної кристалізації.
UA4356076A 1987-07-16 1988-06-28 СПОСІБ РОЗДІЛЕННЯ СУМІШИ d-І l-ЕНАНТІОМЕРІВ 4-[1- UA5560A1 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8716803A GB2206880B (en) 1987-07-16 1987-07-16 Optical isomers of an imidazole derivative

Publications (1)

Publication Number Publication Date
UA5560A1 true UA5560A1 (uk) 1994-12-28

Family

ID=10620775

Family Applications (1)

Application Number Title Priority Date Filing Date
UA4356076A UA5560A1 (uk) 1987-07-16 1988-06-28 СПОСІБ РОЗДІЛЕННЯ СУМІШИ d-І l-ЕНАНТІОМЕРІВ 4-[1-

Country Status (29)

Country Link
US (1) US4910214A (uk)
EP (1) EP0300652B1 (uk)
JP (1) JPH0625138B2 (uk)
KR (1) KR940007311B1 (uk)
CN (1) CN1022323C (uk)
AT (1) ATE71941T1 (uk)
AU (1) AU600839B2 (uk)
BG (1) BG60473B2 (uk)
CA (1) CA1337659C (uk)
CY (2) CY1787A (uk)
DD (1) DD281807A5 (uk)
DE (2) DE10399005I2 (uk)
DK (1) DK165788C (uk)
ES (1) ES2038757T3 (uk)
FI (1) FI95375C (uk)
GB (1) GB2206880B (uk)
GR (1) GR3003878T3 (uk)
HK (1) HK56094A (uk)
HU (1) HU198693B (uk)
IE (1) IE60456B1 (uk)
IL (1) IL87076A0 (uk)
LU (1) LU91010I2 (uk)
NL (1) NL300117I2 (uk)
NO (2) NO170579C (uk)
NZ (1) NZ225362A (uk)
PT (1) PT88013B (uk)
SU (1) SU1648248A3 (uk)
UA (1) UA5560A1 (uk)
ZA (1) ZA885134B (uk)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2215206B (en) * 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB2281206A (en) * 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
IN187238B (uk) * 1995-06-30 2002-03-09 Astra Ab
GB9521680D0 (en) * 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
US5866579A (en) 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
DE60024855T2 (de) 1999-10-29 2006-08-31 Orion Corp. Verwendung eines imidazolderivats zur behandlung oder verhütung von hypotension und schock
US6388090B2 (en) * 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
EP1956906A4 (en) 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
BRPI0709606B8 (pt) 2006-03-16 2021-05-25 Tris Pharma Inc suspensão líquida administrável oralmente com características de liberação modificada
US7795263B2 (en) * 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
EP2370136A4 (en) * 2008-12-01 2015-12-30 Map Pharmaceuticals Inc INHALATIVE RELEASE PROCEDURES AND DEVICES
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
NZ596976A (en) * 2009-05-15 2014-05-30 Recro Pharma Inc Sublingual dexmedetomidine compositions and methods of use thereof
CN101671305A (zh) * 2009-09-29 2010-03-17 北京华禧联合科技发展有限公司 一种拆分美托咪定的左旋及右旋对映体的方法
CN102464619A (zh) * 2010-11-17 2012-05-23 桑迪亚医药技术（上海）有限责任公司 一种左旋4-[1-(2,3-二甲基苯基)乙基]-1r-咪唑消旋化方法
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
WO2013069025A1 (en) 2011-11-11 2013-05-16 Neon Laboratories Ltd. "process for the preparation of dexmedetomidine"
SG11201403094TA (en) 2011-12-11 2014-10-30 Recro Pharma Inc Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
ITMI20120311A1 (it) * 2012-02-29 2013-08-30 Edmond Pharma Srl Procedimento per la risoluzione di medetomidina e recupero dell'enantiomero indesiderato
AU2013302657B2 (en) 2012-08-15 2018-08-09 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
DK2906213T3 (en) * 2012-10-15 2018-02-19 Orion Corp VETERINARY PROCEDURE FOR RELIEFING NOISE SENSITIVITY
ES2856189T3 (es) 2013-10-07 2021-09-27 Teikoku Pharma Usa Inc Métodos y composiciones para el tratamiento del trastorno de hiperactividad por déficit de atención, ansiedad e insomnio utilizando composiciones transdérmicas de dexmedetomidina
ES2847936T3 (es) 2013-10-07 2021-08-04 Teikoku Pharma Usa Inc Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina
KR101827980B1 (ko) 2013-10-07 2018-02-13 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
CN105175339B (zh) * 2015-10-09 2018-01-16 辰欣药业股份有限公司 一种制备盐酸右美托咪定的方法
US9717796B1 (en) 2016-04-20 2017-08-01 Slypharma, Llc Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
FR3054218B1 (fr) * 2016-07-22 2020-03-06 Universite De Rouen Procede de dedoublement de sels de baclofene
US11160791B2 (en) 2018-11-01 2021-11-02 Medefil, Inc. Dexmedetomidine injection premix formulation in ready to use (RTU) bags
CN114671811A (zh) * 2022-04-14 2022-06-28 南京正科医药股份有限公司 一种右美托咪定拆分副产物的外消旋化回收方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
GB2092569B (en) * 1981-02-05 1984-09-19 Farmos Oy Substituted imidazole derivatives and their preparation and use
GB2101114B (en) * 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
DE3531682A1 (de) * 1985-09-05 1987-03-12 Thomae Gmbh Dr K (+)-6-chlor-5,10-dihydro-5-((1-methyl-4- piperidinyl)acetyl)-11h-dibenzo(b,e)(1,4) diazepin-11-on, seine isolierung und verwendung als arzneimittel

Also Published As

Publication number Publication date
US4910214A (en) 1990-03-20
NL300117I1 (nl) 2003-05-01
EP0300652A1 (en) 1989-01-25
GB8716803D0 (en) 1987-08-19
NO170579C (no) 1992-11-04
ATE71941T1 (de) 1992-02-15
FI882819A0 (fi) 1988-06-14
BG60473B2 (bg) 1995-04-28
DE10399005I2 (de) 2012-06-06
CA1337659C (en) 1995-11-28
ZA885134B (en) 1989-04-26
HU198693B (en) 1989-11-28
NO2003004I2 (no) 2005-03-21
FI95375B (fi) 1995-10-13
KR890002030A (ko) 1989-04-07
NO883155D0 (no) 1988-07-15
IE60456B1 (en) 1994-07-13
DE10399005I1 (de) 2003-06-05
HUT48218A (en) 1989-05-29
DK165788C (da) 1993-06-14
KR940007311B1 (ko) 1994-08-12
AU600839B2 (en) 1990-08-23
DK165788B (da) 1993-01-18
PT88013B (pt) 1995-03-01
PT88013A (pt) 1989-06-30
ES2038757T3 (es) 1993-08-01
GB2206880B (en) 1991-04-24
NL300117I2 (nl) 2003-10-01
GB2206880A (en) 1989-01-18
JPS6434968A (en) 1989-02-06
NO170579B (no) 1992-07-27
FI95375C (fi) 1996-01-25
DK386288D0 (da) 1988-07-11
NO883155L (no) 1989-01-17
DE3867945D1 (de) 1992-03-05
CY1787A (en) 1995-10-20
LU91010I2 (fr) 2003-06-19
IL87076A0 (en) 1988-12-30
SU1648248A3 (ru) 1991-05-07
DK386288A (da) 1989-01-17
NZ225362A (en) 1990-07-26
DD281807A5 (de) 1990-08-22
AU1894188A (en) 1989-01-19
CN1030576A (zh) 1989-01-25
GR3003878T3 (uk) 1993-03-16
EP0300652B1 (en) 1992-01-22
HK56094A (en) 1994-06-03
CY2004006I1 (el) 2009-11-04
CY2004006I2 (el) 2009-11-04
JPH0625138B2 (ja) 1994-04-06
FI882819L (fi) 1989-01-17
CN1022323C (zh) 1993-10-06
IE882174L (en) 1989-01-16

Similar Documents

Publication Publication Date Title
UA5560A1 (uk) СПОСІБ РОЗДІЛЕННЯ СУМІШИ d-І l-ЕНАНТІОМЕРІВ 4-[1-
HUT62575A (en) Process for producing substituted imidazole derivatives and pharmaceutical compositions comprising same
ES2053864T3 (es) Derivados de acido 4-(quinolin-2-il-metoxi)fenil-acetico substituido.
PT94377A (pt) Processo de preparacao de acidos imidazolilalcenoicos e de composicoes farmaceuticas que os contem
NO176049C (no) Analogifremgangsmåte for fremstilling av terapeutiske imidazoler som blokkerer angiotensin-II-reseptorer
GB8804683D0 (en) 4-substituted imidazole derivatives useful in perioperative care
ZA858416B (en) A therapeutically useful compound
PH25106A (en) 1-acyl-3-(4-(2-pyrimidinyl)-1-piperazinyl) propanes, pharmaceutical composition containing said compound and method of use thereof
AU547319B2 (en) 1-(3-halo-2-pyridinyl) piperazine
ES8704927A1 (es) Procedimiento para preparar 2(1h)-piridonas
ATE36854T1 (de) Tetrahydrothienopyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel.
HUT36124A (en) Process for preparing sorbinyl by means of the resolution of 6-fluoro-4-ureido-chromane-4-carboxylic acid
PH25682A (en) A process for the preparation of 1-(1-aryl-2-hydroxyethyl)-imidazoles, salts thereof
JPS6478328A (en) Interruption control system
LV5241A3 (lv) enantiomeru maisijuma sadalisanas metode 4-Ú1-(2,3-dimetilfenil)etil¾-1h-imidazola d- un l-
ATE124048T1 (de) Verfahren zur herstellung von beta-lactamase- inhibitoren.
GR860680B (en) Novel imidazolyl compounds and method for their preparation
DK157134C (da) Analogifremgangsmaade til fremstilling af 1-(5-chlorpyrid-2-yl)-1-(2,4-dihalogenphenyl)-2-(1,2,4-triazol-1-yl)-ethanol-forbindelser eller deres farmaceutisk acceptable syreadditionssalte
IT1190818B (it) Procedimento per la produzione di alfa-aminoderivati ciclici di 1-(3',4'-metilendiossifenil)etanolo
ES8301933A1 (es) "procedimiento para la preparacion de derivados de 4-(5)-alcohil-mercaptoimidazoles".
ES2001449A6 (es) Nuevo metodo de sintesis del bifonazol
ES8506040A1 (es) Un procedimiento de preparacion de sorbinil o una sal cationica farmaceuticamente aceptable del mismo
NZ240736A (en) Racemic or dextro 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole or its salts so as to reduce stress on the nervous system prior to surgical operations